MRK•benzinga•
Merck Enters Exclusive Global License With LaNova For LM-299, A Novel Investigational PD-1/VEGF Bispecific Antibody; LaNova To Receive Upfront Payment Of $588 And Receive Up To $2.7B In Milestone Payments
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 14, 2024 by benzinga